0000000001191201

AUTHOR

C Kim

showing 4 related works from this author

Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone

2016

BACKGROUND The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate. METHODS In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 weeks. All the patients had a history of a severe asthma exacerbation in t…

Maleasthma ; serious events ; fluticasone ; salmeterol ; AUSTRIExacerbationIntention to Treat AnalysiINHALED CORTICOSTEROIDSSeverity of Illness Indexlaw.invention0302 clinical medicineRandomized controlled triallawimmune system diseasesÚs terapèuticBroncodilatadors030212 general & internal medicineChildFluticasoneRISKACTING BETA-AGONISTS; INHALED CORTICOSTEROIDS; RISK; EXACERBATIONS; METAANALYSIS; MORTALITY; SAFETY; DEATH; FDAMedicine (all)Hazard ratioDEATHGeneral MedicineBronchodilator agentsMiddle AgedFluticasone-Salmeterol Drug CombinationBronchodilator AgentsIntention to Treat AnalysisAnesthesiaSAFETYFemaleSalmeterolFDAmedicine.drugHumanAdultmedicine.medical_specialtyAdolescentSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionate03 medical and health sciencesDouble-Blind MethodInternal medicineAdministration InhalationmedicineHumansMETAANALYSISAsmaBronchodilator AgentAsthmaAgedProportional Hazards ModelsFluticasone-Salmeterol Drug Combinationbusiness.industryMORTALITYACTING BETA-AGONISTSTherapeutic usemedicine.diseaseAsthmarespiratory tract diseasesEXACERBATIONS030228 respiratory systemFluticasone Propionate Salmeterol Xinafoate Drug CombinationProportional Hazards ModelFluticasonebusiness
researchProduct

Two-particle transverse momentum correlations in pp and p-Pb collisions at energies available at the CERN Large Hadron Collider

2023

Two-particle transverse momentum differential correlators, recently measured in Pb--Pb collisions at energies available at the CERN Large Hadron Collider (LHC), provide an additional tool to gain insights into particle production mechanisms and infer transport properties, such as the ratio of shear viscosity to entropy density, of the medium created in Pb-Pb collisions. The longitudinal long-range correlations and the large azimuthal anisotropy measured at low transverse momenta in small collision systems, namely pp and p-Pb, at LHC energies resemble manifestations of collective behaviour. This suggests that locally equilibrated matter may be produced in these small collision systems, simil…

two particle correlations large hadron colliderCERN Lablongitudinallarge hadron colliderheavy ion scatteringcollectiveFOS: Physical sciencesanisotropy measuredtransverse momentum correlation[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex]High Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)transport theoryTeVcorrelation functionNuclear Experiment (nucl-ex)Nuclear ExperimentMonte Carloeffect viscositycorrelation long-rangetwo-particleentropy densityparticle multiplicityCERN LHC Collangular distribution anisotropybroadeningtransverse momentum lowydinfysiikkatwo particle correlations
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

Gravitational Waves and Gamma-Rays from a Binary Neutron Star Merger: GW170817 and GRB 170817A

2017

On 2017 August 17, the gravitational-wave event GW170817 was observed by the Advanced LIGO and Virgo detectors, and the gamma-ray burst (GRB) GRB 170817A was observed independently by the Fermi Gamma-ray Burst Monitor, and the Anticoincidence Shield for the Spectrometer for the International Gamma-Ray Astrophysics Laboratory. The probability of the near-simultaneous temporal and spatial observation of GRB 170817A and GW170817 occurring by chance is $5.0\times 10^{-8}$. We therefore confirm binary neutron star mergers as a progenitor of short GRBs. The association of GW170817 and GRB 170817A provides new insight into fundamental physics and the origin of short gamma-ray bursts. We use the ob…

AstrofísicaGravitacióneutron star: binaryclose [binaries]Astronomy[ PHYS.ASTR ] Physics [physics]/Astrophysics [astro-ph]BATSE OBSERVATIONSgamma-ray burst: generalEQUIVALENCE PRINCIPLEEXTENDED EMISSIONastro-ph.HE; astro-ph.HEAstrophysicsKilonovageneral [gamma-ray burst]01 natural sciences7. Clean energyGeneral Relativity and Quantum Cosmologyphoton: velocityPROMPT EMISSIONLIGOclose gamma-ray burst: general gravitational waves [binaries]gravitational wave010303 astronomy & astrophysicsGeneralLiterature_REFERENCE(e.g.dictionariesencyclopediasglossaries)BURST SPECTRAQCQBPhysicsastro-ph.HEHigh Energy Astrophysical Phenomena (astro-ph.HE)binaries: closeGRBEQUATION-OF-STATEviolation: Lorentzgamma ray: emissiongravitational wavesAstrophysics - High Energy Astrophysical PhenomenaGWradiation: electromagneticAfterglow Light CurvesAstrophysics::High Energy Astrophysical PhenomenaFOS: Physical sciencesGeneral Relativity and Quantum Cosmology (gr-qc)Astrophysics::Cosmology and Extragalactic Astrophysicsgamma ray: burstinvariance: LorentzGW GRB LIGO Virgo Fermi BNSGLASTOptical Afterglows0103 physical sciencesgamma ray: detectorBinaries: close; gamma-ray burst: general; gravitational wavesSTFCFermi010308 nuclear & particles physicsGravitational waveVirgogravitational radiationRCUKAstronomy and AstrophysicsAstronomy and Astrophysictime delaysensitivityShapiro delayLIGORedshiftNeutron starVIRGOPhysics and AstronomyHOST GALAXYCPT VIOLATION13. Climate actiongravitationSpace and Planetary ScienceLUMINOSITY FUNCTIONVIEWING ANGLEbinaries: close; gamma-ray burst: general; gravitational waves; Astronomy and Astrophysics; Space and Planetary ScienceBNSspectrometerGamma-ray burst[PHYS.ASTR]Physics [physics]/Astrophysics [astro-ph]redshift: measuredFermi Gamma-ray Space TelescopeAstrophysical Journal Letters
researchProduct